156451-00-2

Upstream product

• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 1577-20-4 (E)-hex-4-enoic acid 

Downstream Products

• 178615-13-9 (S)-4-Benzyl-3-((E)-(R)-2-benzyl-hex-4-enoyl)-oxazolidin-2-one 
• 178615-14-0 C₁₇H₁₇⁽²⁾H₃FNO₃ 
• 178615-15-1 (S)-4-Benzyl-3-((E)-(S)-2-benzyl-2-fluoro-hex-4-enoyl)-oxazolidin-2-one 
• 178615-20-8 (E)-(S)-2-Benzyl-2-fluoro-hex-4-enoic acid 
• 178615-21-9 (E)-(R)-2-Benzyl-hex-4-enoic acid 
• 178615-11-7 (S)-4-Benzyl-3-((E)-(S)-2-fluoro-hex-4-enoyl)-oxazolidin-2-one 
• 178615-12-8 (S)-4-Benzyl-3-((E)-(S)-2-ethyl-hex-4-enoyl)-oxazolidin-2-one 
• 156451-01-3 C₁₇H₁₈⁽²⁾H₃NO₃ 

Relevant academic research and scientific papers

A Synthetic Route to β-Hydroxytyrosine-Derived Tetramic Acids: Total Synthesis of the Fungal Metabolite F-14329

3-Acyltetramic acids derived from β-hydroxytyrosine are synthetically challenging. The first route to this structural motif, based upon a condensation between a Meldrum's acid conjugate bearing the acyl side chain, and a β-hydroxytyrosinate, N-protected by an ortho-nitrobenzyl group is presented. This group enables the Dieckmann cyclization of the resulting N-(β-ketoacyl)amino ester, after which it can be removed photolytically without compromising the delicate 3′-hydroxy group. This strategy was applied to the first total synthesis of the fungal metabolite F-14329 (1).

Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Compounds for inhibiting β-amyloid peptide release and/or its synthesis

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis.

Compounds for inhibiting β-amyloid peptide release and/or its synthesis

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis.

Biosynthesis of tetronasin: Part 6. Preparation of structural analogues of the diketide and triketide biosynthetic precursors to tetronasin

The preparation of three analogues of the putative diketide biosynthetic precursor (2) and eight analogues of the putative triketide biosynthetic precursor (3) of the acyl tetronic acid ionophore tetronasin, as N-acetylcysteamine thioesters (4), (5), (6), (12), (13), (14), (15), (22), (23), (24) and (25) is described. Five examples are 19F-labelled; a new, enantiospecific method for the creation of a fluorinated quarternary α-centre is presented.

Biosynthesis of Tetronasin: Part 3. Preparation of Deuterium Labelled Tri- and Tetraketides as Putative Biosynthetic Precursors of Tetronasin

The preparation of seven deuterium labelled N-acetyl cysteamine thioesters (2a), (2b), (3a), (3b), (4), (5) and (6) as putative biosynthetic precursors of the acyl tetronic acid ionophore tetronasin is described.